Image

A Chitosan Brush and Enamel Matrix Derivative for Non-surgical Treatment of Furcations

A Chitosan Brush and Enamel Matrix Derivative for Non-surgical Treatment of Furcations

Recruiting
18 years and older
All
Phase N/A

Powered by AI

Overview

Patients diagnosed with stage III or IV periodontitis who exhibit mandibular first or second molars with Class II, Subclass A, or B buccal and/or lingual mandibular furcation defects (horizontal probing depth of ≥ 3 mm ) will be recruited.

Patients diagnosed with stage III or IV periodontitis who exhibit maxillary first or second molars with Class II, Subclass A, or B buccal furcation defects (horizontal probing depth of ≥ 3 mm ) if furcation involvement on the palatal side (mesiopalatal and distopalatal) does not exceed Class 1 will be recruited.

This study will be a prospective, randomized, single-blinded, controlled clinical trial with a split-mouth design.

Patients will be recruited from the clinics of the Riga Stradiņš University Institute of Stomatology of Riga, Latvia.

Before the baseline treatment, all patients who meet the inclusion criteria will be given detailed oral hygiene instructions and motivation.

Patients' furcation defects in each quadrant will be randomly allocated at a 1:1 ratio to either the application of Oscillating Chitosan Brush with Enamel Matrix Derivatives (test group) or Oscillating Chitosan Brush alone (control group).

Non-surgical periodontal treatment of furcation defects on the test side will be performed through the application of Oscillating Chitosan Brush with Enamel Matrix Derivatives and on the control side with Oscillating Chitosan Brush alone.

The re-evaluation of periodontal status will be performed 12 weeks following the baseline treatment.

Biofilm samples and gingival crevicular fluid (GCF) samples will be taken at the baseline and at 4 weeks.

Eligibility

Inclusion criteria:

  1. The patient is 18 years of age or older
  2. The patient does not have any systemic diseases that may affect the results of the study
  3. The patient has a plaque index of 20% or less at the study entry
  4. The patient has a history of severe localized or generalized periodontitis (stage III or IV)
  5. Completed the first and second steps of periodontal treatment (According to Treatment of stage I-III periodontitis-The EFP S3 level clinical practice guideline) (Sanz M. et al.)
  6. Buccal and/or lingual Class 2A and/or 2B furcation involvement (FI) defects on both sides of the Mandibular first and/or second molars after completing the first and second steps of periodontal treatment.
  7. Buccal Class 2A and/or 2B furcation involvement (FI) defects on both sides of the maxillary first and/or second molars after completion of the first and second step of periodontal treatment if furcation involvement on the palatal side (mesiopalatal and distopalatal) does not exceed Class 1.
  8. Psychological appropriateness
  9. Consents to all follow-up visits

Exclusion Criteria:

  1. Patients who have systemic diseases that may affect the results of the study
  2. Use of medications that may affect study results (anti-osteoporotic drugs, statins, corticosteroids, anticoagulants)
  3. Patients who use calcium channel blockers, cyclosporine A or antiepileptic drugs if there are clinically visible hyperplastic changes in the gingival margin.
  4. Patients who have received any type of systemic antibiotics in the last six months prior to the start of the study and patients starting antibiotics during the study
  5. Patients requiring antibiotic premedication prior to periodontal treatment
  6. Oncological disease
  7. Chemotherapy and/or radiotherapy (active or history)
  8. Pregnancy and breastfeeding
  9. Any condition or current treatment which, in the opinion of the investigator and/or consulting physician, may present an unreasonable risk
  10. Psychoemotional disorders and depression
  11. Use of antipsychotic medication or antidepressants
  12. Lack of patient motivation to undertake adequate dental care at home or complete periodontal treatment, patients residing outside Latvia
  13. Molars with combined endodontic-periodontal lesions, active endodontic infection
  14. Prosthetic factors for molars not allowing clinical measurements
  15. Huge restoration or amalgam fillings that could potentially cause fractures or furcation involvement
  16. Enamel pearls or filling or crown margins
  17. Decay or root resorption
  18. Tooth mobility degree 3
  19. Molars in which the gingival margin is positioned apically from the entrance into the furcation area
  20. Clinical attachment level and or pockets mesial and distal to the furcation involvement defect of 6 or more mm
  21. Strong vomiting reflex that would prevent adequate periodontal treatment
  22. People close to the study subjects, work colleagues, relatives, etc.

Study details
    Periodontitis
    Adult
    Furcation Defects
    Furcation of Root of Tooth
    Periodontitis Complex

NCT06684769

Riga Stradins University

16 October 2025

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.